IMItai Margulis

Itai Margulis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Itai Margulis has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Nili Stein

    Department of Community Medicine and Epidemiology, The Lady Davis Carmel Medical Center, Haifa, Israel

    2 shared publications
  • Raanan Cohen-Kerem

    Pediatric otolaryngology unit, Department of Otolaryngology Head and Neck Surgery, The Lady Davis Carmel Medical Center, Haifa, Israel; Rappaport Faculty of Medicine, Technion, Haifa, Israel

    2 shared publications
  • Arie Gordin

    Department of Otolaryngology-Head and Neck Surgery, Rambam Health Care Campus, Haifa, Israel

    1 shared publication
  • Ariel Aviram

    Department of Otolaryngology Head and Neck Surgery, Lady Davis Carmel Medical Center, and the Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel

    1 shared publication
  • Ariel Roitman

    Department of Otolaryngology-Head and Neck Surgery, The Lady Davis Carmel Medical Center, Haifa, Israel; The Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel

    1 shared publication
  • Ariel Roitman

    Department of Otolaryngology - Head and Neck Surgery, Carmel Medical Center, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel

    1 shared publication

Latest Publications

  • Open Access

    Geographic Disparities in Evidence Investigating the Use of Biologics in Chronic Rhinosinusitis

    by Itai Margulis, Mohd Afiq Mohd Slim, Ethan C. Sommer, Tatiana Haidar, Zahra Abdallah, Yousif AlAmmar, Sarah Khalife, Doron D. Sommer

    Importance: Despite a surge in the volume of evidence assessing the safety and efficacy of biologics for the treatment of chronic rhinosinusitis (CRS), nuances relating to geographic variations in this literature remain insufficiently elucidated. Objective: To assess the diversity and representation of populations within the literature investigating the use of biological agents for CRS. Design/Setting: Systematic review. Participants: Adults ≥18 years with CRS treated with biologic agents. Interventions: Following PRISMA guidelines, 2 complementary analyses of all studies published between 2006 and 2023 (analysis A), and randomized controlled trials (RCT) and real-world (RW) studies published between 2006 and 2025 (analysis B) were performed. Main outcomes measures: Patients’ number and country of origin, race/ethnicity, authors’ affiliated countries and Human Development Index (HDI). Types of biologics agents and metrics of the publications were collected. Results: Out of 2768 studies reviewed, 169 were included in the final analyses. Dupilumab was the most studied biologic agent (37.8%), followed by mepolizumab. The United States had the highest absolute representation and Belgium the highest number of authors per capita, which was correlated with patients’ nationality. The majority of the journals’ and authors’ country of origin was the United States. Only 19 (11.2%) studies disclosed patients’ race/ethnicity, with Asian and Caucasian subjects most commonly represented. The authors’ HDI correlated with journals’ H-index and impact factor. Sixty-seven studies (39.6%) had industry funding, with dupilumab representing the highest number (15.9%). Conclusion: Although the use of biologics has shown promising results in the management of CRS, most of the evidence comes from the United States and Europe. There is a paucity of representation from certain regions, including Africa, Latin America, and Asia, and inadequate overall disclosure of race/ethnicity in existing studies. This warrants further high-quality investigation of biological agents’ safety and efficacy among these underrepresented populations. Relevance: Addressing gaps in clinical studies is important for furthering understanding of the pathophysiology and pharmacology of biologic agents for CRS, and bridging treatment disparities.

  • Open Access

    Rhinitis medicamentosa – comparing two treatment strategies: a retrospective analysis

    by Itai Margulis, Jenny Jrbashyan, Sivan Bitterman Fisher, Nir Feibish, Nili Stein, Raanan Cohen-Kerem

    Objective: Rhinitis medicamentosa poses a therapeutic challenge for both patients and physicians. Treatment strategies vary, starting with avoidance of decongestants, followed by medications or surgical intervention. This study aimed to compare two treatment strategies for this condition.Methods: A review was conducted of patients diagnosed with rhinitis medicamentosa from 2013 to 2021, who were managed conservatively with medications or surgically by inferior turbinate reduction.Results: Forty-seven patients were included: 21 patients were treated conservatively and 26 underwent turbinate reduction. Following surgical therapy, the frequency of using decongestants was significantly reduced (p < 0.001), with a significant improvement in Sino-Nasal Outcome Test-22 scores (p < 0.001). The conservative treatment group was significantly older with more co-morbidities. Following medical therapy, the conservative treatment group had a significant decrease in the frequency of decongestant use, but there was no significant improvement in their Sino-Nasal Outcome Test-22 scores.Conclusion: Compared to conservative treatment, inferior turbinate reduction for rhinitis medicamentosa resulted in reduced decongestant use and improved quality of life.


  • Xylitol nasal spray for prevention of recurrent acute otitis media in children: A prospective two-center cohort study

    by Itai Margulis, Raanan Cohen-Kerem, Nili Stein, Ariel Roitman, Mauricio Cohen-Vaizer, Eran Fridman, Arie Gordin


  • Open Access

    Laboratory and imaging findings of necrotizing otitis externa are associated with pathogen type and disease outcome: A retrospective analysis.

    by Itai Margulis, Raanan Cohen-Kerem, Ariel Roitman, Hadar Gez-Reder, Ariel Aviram, Sivan Bitterman-Fisher, Nir Kugelman, Ilana Doweck

    Objective: To examine associations of laboratory and imaging data with diagnostic parameters of necrotizing otitis externa (NOE) and its severity, and to compare between bacterial and fungal infections. Methods: Records of patients diagnosed with NOE during 2010–2018 at the Department of Otolaryngology, Head and Neck Surgery were reviewed retrospectively for demographics; disease characteristics; and laboratory, scintigraphy, and imaging results. Results: Of 48 patients with NOE, the mean age is 73±11.6 years; 32 (67%) were males; 83% had diabetes mellitus. Common pathogens were pseudomonas (49%) and fungi (33%). Sensitivities of the technetium-scan (SPECT ratio ≥1.5), temporal bone computed tomography (CT), and gallium-scan (SPECT ratio ≥1.3) were: 78.7%, 48.8%, and 31.4%, respectively. Gallium-scan results correlated positively with CT bone involvement (p=0.002) and hospital length of stay (p=0.0014). C-reactive protein (CRP) level correlated with hospital length of stay (p=0.028) and positive technetium-scan results (p=0.012). Fungal infection had a higher technetium SPECT ratio (2.16 vs. 1.77, p=0.04), gallium SPECT ratio (1.4 vs. 1.2, p=0.02), longer duration of systemic treatment (87.4 vs. 37.9 days, p=0.014), and longer hospital length of stay (31.6 vs. 15.2 days, p=0.004) compared to non-fungal infection. Eight (17%) patients had responded poorly to treatment. Fungal pathogens, facial nerve paresis, extra-auricular, and bilateral disease were more prevalent among the non-responders. Conclusion: The technetium scan has higher sensitivity than temporal bone CT for diagnosing NOE. The gallium scan and CRP correlated well with hospital length of stay. A high rate of fungal infection was found, with significantly higher technetium and gallium SPECT ratios and worse outcome compared to bacterial infection. Fungal NOE remains therapeutically challenging.